Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Splitting pazopanib intake moments to increase exposure
2016-005252-21Phase 4Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC) and soft tissue sarcoma (STS), sponsored by Netherlands Cancer Institute. Primary endpoint: Increase in pharmacokinetic exposure. Started Mar 2017; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2016-005252-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005252-21.